Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Lancet Oncol. 2020 Nov 27;22(1):107–117. doi: 10.1016/S1470-2045(20)30540-4

Figure 1: Trial profile.

Figure 1:

HGRF=high-grade recurrence-free. *Post-enrolment review of medical records. †Defined in the final Statistical Analysis Plan. Five patients in the carcinoma in situ Ta or T1 cohort and three patients in the high-grade Ta or T1 cohort progressed to detrusor muscle invasion (≥pT2) by data cutoff.